Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...

Q1 2025 Earnings Call Transcript May 12, 2025 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for central nervous system and oncology-related conditions. Its lead candidates, NDV-01 ...

High-risk NMIBC is characterised by poor prognosis, with half of patients recurring despite effective treatment with the ...

In 2017, seven-time NASCAR Cup Series champion Jimmie Johnson received a cancer diagnosis. The post Amidst Battling Cancer ...

Colin P.N. Dinney, MD, provides some background on translational analyses from the BOND-003 and CORE-001 trials.

You’ve probably heard of stages 1, 2, 3 and 4 – but there’s another diagnosis of cancer that you might not have heard of.

Women diagnosed with DCIS face a threefold higher risk of breast cancer mortality. Learn the warning signs, treatment options ...

Research and development expenses for the first quarter of 2025 increased to $9.1 million from $7.7 million for the prior ...

A woman from Mayo campaigning for mandatory dense breast tissue reports for women receiving mammograms will be part of a ...